Meglitinides (Glinides)

Mechanism of action and pharmacological profile

Glinides are regulators of post-meal blood sugar levels (postprandial glycemia). Their primary goal is the prevention and management of postprandial hyperglycemia.

• Insulin secretion: the drugs block ATP-sensitive $K^+$ channels in pancreatic $eta$-cells, causing membrane depolarization. This leads to the opening of $Ca^{2+}$ channels and subsequent insulin exocytosis.
• Physiological action: unlike sulfonylureas, glinides restore the early, glucose-stimulated phase of insulin release.
• Glucose-dependence: the agents have little effect on basal secretion. A drop in glucose levels automatically halts the stimulation of insulin release, minimizing the risk of hypoglycemia if a meal is missed.
• Safety: high selectivity for pancreatic channels (exceeding cardiovascular receptors by 300-fold) ensures cardiovascular safety.

Characteristics of Nateglinide

Nateglinide (trade name Starlix) is a phenylalanine amino acid derivative and a prominent representative of meglitinides.

• Pharmacokinetics: the drug is rapidly absorbed orally, with a bioavailability of about 72%. Maximum plasma concentration is reached in less than an hour.
• Metabolism and excretion: metabolism occurs in the liver via cytochrome P450 isoenzymes, forming active hydroxylated metabolites. The half-life ($T_{1/2}$) is about 1.5 hours, and the drug is excreted primarily by the kidneys—up to 83% in the urine.
• Administration guidelines: the medication is taken orally immediately before a meal, with the interval between taking the tablet and starting the meal not exceeding 30 minutes.

Features of Repaglinide

Repaglinide is another key representative of the group, being a benzoic acid derivative and a structural analogue of nateglinide.

• Excretion routes: unlike nateglinide, this drug is excreted mainly through the bile rather than the kidneys.
• Clinical advantage: due to this excretion profile, repaglinide is officially approved for use in patients with comorbid renal disease.
• Pharmacological effect: provides a rapid onset of maximum blood glucose-lowering action within the first 15 minutes after a meal, effectively controlling glucose spikes.

Side effects and safety profile

Like any hypoglycemic agents, glinides have a specific spectrum of adverse reactions:

• Hypoglycemia: the main side effect. Manifests as tremor, excessive sweating, tachycardia, dizziness, general weakness, and a sharp sensation of hunger.
• Gastrointestinal and hepatic: dyspeptic disorders, abdominal pain, and hepatotoxicity manifested by elevated liver enzymes are possible.
• Special senses: transient visual disturbances caused by glycemic fluctuations may occur at the start of therapy.
• Allergic manifestations: pruritus, rash, urticaria, and rare changes in the peripheral blood picture.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• Pleiotropic effects: antioxidant protection and stimulation of alpha-tocopherol synthesis
• Metabolic action in tissues via phospholipase C
• Pharmacokinetic differences of cytochrome P450 in nateglinide metabolism
• Features of repaglinide excretion via the hepatobiliary system
• Comparative analysis of transient visual disturbances at the start of therapy

Other topics in the section "Hormone preparations, their synthetic substitutes, and antagonists"

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.